Market Insights Health Hospitals Inpatient Care

Treatment of Cardiovascular Diseases - ASEAN

ASEAN

The Treatment of Cardiovascular Diseases market in ASEAN is anticipated to generate a revenue of US$11.77bn in 2025.
It is expected to exhibit a compound annual growth rate (CAGR 2025-2029) of 7.11%, leading to a market volume of US$15.49bn by 2029.
Comparatively, United States will generate the highest revenue in the global market, amounting to US$140.40bn in 2025.
In the ASEAN region, Singapore is leading the way in the treatment of cardiovascular diseases with its advanced medical technology and highly skilled healthcare professionals.

Key regions: Germany, France, Japan, Europe, India

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.